Gene Besen advises corporations and individuals across the country in navigating investigations, civil enforcement actions and criminal proceedings brought by various government agencies. He represents clients in a wide range of industries – including healthcare, telemedicine, pharmaceuticals, financial services, and others – that need proactive strategies to mitigate and avoid controversies related to allegations involving billing fraud, kickbacks, securities fraud, insider trading, FCPA violations, pay-to-play schemes, antitrust violations and price fixing.
Gene has guided clients to favorable outcomes in investigations and criminal prosecutions brought by the enforcement agencies that oversee their activities, including the Department of Justice (DOJ), Department of Health and Human Services, Securities and Exchange Commission (SEC), Financial Industry Regulatory Authority (FINRA) and Texas State Securities Board. Focused on preventing government intervention altogether, he regularly helps clients develop compliance policies and conduct internal investigations and audits to identify emerging issues before they become problems.
Gene also has extensive experience representing telemedicine companies, hospitals, physicians, pharmacies, laboratories, pharmaceutical corporations, financial institutions, hedge funds and utilities in a wide range of civil and commercial litigation matters. These disputes typically involve claims related to white-collar criminal matters, including False Claims Act violations, healthcare fraud, securities fraud, kickbacks and clawback actions involving alleged fraudulent transfers.
His experience handling investigations and enforcement proceedings allows him to help clients expand and protect their businesses. Gene serves as outside general counsel for several entrepreneurs and growing companies across the country, advising on the day-to-day challenges and opportunities that arise during the lifecycle of their businesses.
Government Enforcement and Investigations
© Bradley Arant Boult Cummings LLP, 2021